Genetic and dietary mouse models of obesity and metabolic diseases
Molecular and cellular assays to dissect signaling pathways
Pharmacological modulation of novel targets
Integrated ‘omics and bioinformatics analyses to map systemic changes
In vivo metabolic and behavioral phenotyping analyses
Over the past two decades, obesity and its associated metabolic disorders, including type 2 diabetes, dyslipidemia, fatty liver disease, osteoporosis, and cardiorenal complications, have reached epidemic proportions worldwide. Despite extensive efforts, there remains a critical unmet need for pharmacological treatments that can simultaneously and safely target the diverse pathophysiological consequences of obesity.
Our laboratory is committed to advancing the understanding of metabolic disease pathogenesis and translating that knowledge into effective therapeutic strategies. A major focus of our research centers on the endocannabinoid system (ECS), specifically the peripheral CB1 receptor, which plays a central role in regulating energy balance, lipid metabolism, inflammation, and insulin sensitivity.
We were among the first to demonstrate that peripherally restricted CB1 receptor antagonists can reverse obesity and its metabolic complications, without the neuropsychiatric side effects associated with brain-penetrant compounds. This paradigm-shifting concept has shaped a new wave of drug discovery efforts, aiming to safely modulate the ECS outside the central nervous system. Building on this foundation, we now investigate broader molecular pathways that contribute to metabolic dysfunction, including those beyond the ECS.
Using cutting-edge tools such as transcriptomics, metabolomics, lipidomics, and proteomics, combined with in vivo metabolic phenotyping, advanced imaging, and preclinical drug development, we explore novel targets and mechanisms implicated in metabolic disorders.
Our research is deeply translational in nature. We vastly collaborate with leading basic scientists, academic centers, clinical investigators, and biotech partners to accelerate the path from bench to bedside, moving promising compounds from early discovery through to preclinical efficacy, pharmacokinetics, and safety testing.
Our Research
Translating Endocannabinoid Discoveries into Metabolic Health Solutions
Our Experimental Toolbox Includes
Our Goals
Identify and validate druggable targets involved in metabolic dysfunction
Develop safe and effective therapies for complex metabolic diseases
